MedPath

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Registration Number
NCT02611817
Lead Sponsor
Takeda
Brief Summary

The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.

Detailed Description

The drug being tested in this study is called vedolizumab SC. Vedolizumab SC is being tested to treat people who have moderate to severely active CD. This study will look at clinical remission, as well as enhanced clinical response and corticosteroid-free remission in participants with CD who receive vedolizumab SC maintenance therapy after having achieved a clinical response to vedolizumab IV induction therapy.

The study will enroll approximately 824 participants. All participants will enter a 6 week Induction Phase where they will be administered open-label vedolizumab IV 300 mg via IV infusion at Week 0 (Day 1) and Week 2 (Day 15), and will then be assessed for a clinical response at Week 6. Participants who achieve a clinical response at Week 6 will be randomly assigned to one of the two treatment groups:

* Vedolizumab SC 108 mg Maintenance Arm

* Placebo SC Maintenance Arm

Participants who do not achieve a clinical response will not be randomized into the Maintenance Period, and instead will receive a third infusion of vedolizumab IV 300 mg at Week 6.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 71 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
644
Inclusion Criteria
  1. Diagnosis of CD established at least 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report.

  2. Moderately to severely active CD as determined by a CDAI score of 220 to 450 and 1 of the following:

    • C-reactive protein (CRP) level greater than (>) 2.87 milligram per liter (mg/L) OR
    • Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each >0.5 centimeter [cm] in diameter) or 10 aphthous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD OR
    • Fecal calprotectin >250 microgram per gram (mcg/g) stool during the screening period in conjunction with computed tomography enterography (CTE), magnetic resonance enterography (MRE), contrast-enhanced small bowel radiography, or wireless capsule endoscopy revealing CD ulcerations (aphthae not sufficient).
  3. CD involvement of the ileum and/or colon, at a minimum.

  4. Inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or Tumor necrosis factor-alpha (TNF-α) antagonists.

Read More
Exclusion Criteria
  1. Evidence of abdominal abscess at Screening.
  2. Extensive colonic resection, subtotal or total colectomy.
  3. History of >3 small bowel resections or diagnosis of short bowel syndrome.
  4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  5. Prior exposure to investigational or approved non-biologic therapies (example, cyclosporine, tacrolimus, thalidomide, or tofacitinib) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).
  6. Prior exposure to any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of screening (whichever is longer).
  7. Prior exposure to vedolizumab.
  8. Surgical intervention for CD required at any time during the study.
  9. History or evidence of adenomatous colonic polyps that have not been removed, or of colonic mucosal dysplasia.
  10. Suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.
  11. Active infections.
  12. Chronic hepatitis B virus (HBV) or C (HCV) infection, tuberculosis (TB) (active or latent), or congenital or acquired immunodeficiency. HBV immune participants (that is, being hepatitis B surface antigen [HBsAg] negative and hepatitis B antibody positive) may, however, be included.
  13. History of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Vedolizumab SC 108 mg Maintenance ArmVedolizumab IV 300 mgOpen-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50
Vedolizumab SC 108 mg Maintenance ArmVedolizumab SC 108 mgOpen-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50
Placebo SC Maintenance ArmVedolizumab IV 300 mgOpen-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50
Placebo SC Maintenance ArmPlaceboOpen-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving Clinical Remission at Week 52Week 52

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than or equal to (\<=) 150 at Week 52. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to (=) sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving Enhanced Clinical Response at Week 52Week 52

Enhanced clinical response is defined as a decrease from Baseline of greater than or equal to (\>=) 100 points in the CDAI score at Week 52. A CDAI is a multi-item instrument which measures severity of active CD monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Percentage of Participants Achieving Corticosteroid-free Remission at Week 52Week 52

Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52Week 52

Clinical remission is defined as CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.

Trial Locations

Locations (194)

Royal Melbourne Hospital

🇦🇺

Melbourne, Victoria, Australia

UMHAT 'Tsaritsa Yoanna - ISUL', EAD

🇧🇬

Sofia, Bulgaria

Semmelweis Egyetem

🇭🇺

Budapest, Hungary

Pest Megyei Flor Ferenc Korhaz

🇭🇺

Kistarcsa, Hungary

Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz

🇭🇺

Miskolc, Hungary

HaEmek Medical Center

🇮🇱

Afula, Israel

Hyogo College of Medicine Hospital

🇯🇵

Nishinomiya-shi, Hyogo-Ken, Japan

Gokeikai Ofuna Chuo Hospital

🇯🇵

Kamakura-shi, Kanagawa-Ken, Japan

Kaplan Medical Center

🇮🇱

Rechovot, Israel

IRCCS Ospedale Casa Sollievo della Sofferenza

🇮🇹

San Giovanni Rotondo, Foggia, Italy

Kinshukai Infusion Clinic

🇯🇵

Osaka-shi, Osaka-Fu, Japan

Tokushukai Sapporo Tokushukai Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Sapporo-Kosei General Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Tokushukai Sapporo Higashi Tokushukai Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Santa Familia Centrum Badan, Profilaktyki i Leczenia

🇵🇱

Lodz, Poland

Spitalul Clinic Colentina

🇷🇴

Bucuresti, Romania

SBEIHPE Novosibirsk State Medical University

🇷🇺

Novosibirsk, Russian Federation

Nzoz Vivamed

🇵🇱

Warszawa, Poland

LexMedica Osrodek Badan Klinicznych

🇵🇱

Wroclaw, Poland

BHI of Omsk region Clinical Oncology Dispensary

🇷🇺

Omsk, Russian Federation

SBIH of Yaroslavl region " Regional Clinical Hospital "

🇷🇺

Yaroslavl, Russian Federation

Clinical Helth Centre Zvezdara

🇷🇸

Belgrade, Serbia

SBEI HPE "Rostov State Medical University" of the MoH of the RF

🇷🇺

Rostov-on-Don, Russian Federation

SPb SBIH "City Hospital # 40 of Kurortnyi region"

🇷🇺

Sestroretsk, Russian Federation

SPb SBIH "City Hospital of Saint Martyr Elizaveta"

🇷🇺

St. Petersburg, Russian Federation

SI Institute of Gastroenterology of NAMSU Dept of Stomach & Duodenum Diseases, D&ThN SI DMA of MoHU

🇺🇦

Dnipro, Ukraine

CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC

🇺🇦

Kharkiv, Ukraine

Fakultna nemocnica s poliklinikou F.D. Roosevelta

🇸🇰

Banska Bystrica, Slovakia

RCI Chernivtsi RCH Dep of Surgery HSEI of Ukr Bukovinian SMU

🇺🇦

Chernivtsi, Ukraine

Mackay Memorial Hospital

🇨🇳

Taipei, Taiwan

Univerzitna nemocnica Bratislava, Nemocnica Ruzinov

🇸🇰

Bratislava, Slovakia

Vinnytsia RCH of Veterans of War Dept of Therapy#1 Vinnytsia M.I.Pyrogov NMU

🇺🇦

Vinnytsia, Ukraine

MCIC MC LLC Health Clinic

🇺🇦

Vinnytsia, Ukraine

CI A.and O. Tropiny City Clinical Hospital

🇺🇦

Kherson, Ukraine

Ternopil University Hospital

🇺🇦

Ternopil, Ukraine

Royal Shrewsbury Hospital

🇬🇧

Shrewsbury, Shropshire, United Kingdom

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Hospital de Clinicas de Porto Alegre

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Centro de Investigacion Farmacologica del Bajio, S.C.

🇲🇽

Leon, Guanajuato, Mexico

Arizona Arthritis & Rheumatology Research, PLLC

🇺🇸

Phoenix, Arizona, United States

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

🇧🇷

Sao Jose do Rio Preto, Sao Paulo, Brazil

Middlesex Gastroenterology Associates

🇺🇸

Middletown, Connecticut, United States

Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research

🇺🇸

Chevy Chase, Maryland, United States

Louisiana Research Center, LLC

🇺🇸

Shreveport, Louisiana, United States

Gastroenterology Associates of Central Georgia

🇺🇸

Macon, Georgia, United States

Carle Foundation Hospital

🇺🇸

Urbana, Illinois, United States

Medical Research Center of Connecticut, LLC

🇺🇸

Hamden, Connecticut, United States

Shafran Gastroenterology Center

🇺🇸

Winter Park, Florida, United States

Gastroenterology Associates of Western Michigan, P.L.C.

🇺🇸

Wyoming, Michigan, United States

Gastro-Enterology Research of Lima

🇺🇸

Lima, Ohio, United States

Gastroenterology Group of Naples

🇺🇸

Naples, Florida, United States

Nature Coast Clinical Research, LLC

🇺🇸

Inverness, Florida, United States

Grand Teton Research Group, PLL

🇺🇸

Idaho Falls, Idaho, United States

Gastroenterology Center of the MidSouth PC

🇺🇸

Germantown, Tennessee, United States

Universitair Ziekenhuis Gent

🇧🇪

Gent, Belgium

ZNA Jan Palfijn

🇧🇪

Merksem, Belgium

Allegiance Research Specialists, LLC

🇺🇸

Milwaukee, Wisconsin, United States

Tri-State Gastroenterology Associates

🇺🇸

Crestview Hills, Kentucky, United States

AZ Delta

🇧🇪

Roeselare, Belgium

Gastroenterology Associates, LLC

🇺🇸

Baton Rouge, Louisiana, United States

Clinical Research Institute of Michigan, LLC

🇺🇸

Chesterfield, Michigan, United States

Fiona Stanley Hospital

🇦🇺

Murdoch, Western Australia, Australia

Royal Adelaide Hospital

🇦🇺

Adelaide, South Australia, Australia

Long Island Clinical Research Associates

🇺🇸

Great Neck, New York, United States

Ehrhardt Clinical Research, LLC

🇺🇸

Belton, Missouri, United States

St John of God Subiaco Hospital

🇦🇺

Subiaco, Western Australia, Australia

Imeldaziekenhuis

🇧🇪

Bonheiden, Belgium

AZ Groeninge - Kennedylaan

🇧🇪

Kortrijk, Belgium

HUGG - Hospital Universitario Gaffree e Guinle

🇧🇷

Rio de Janeiro, Rio Do Janeiro, Brazil

Irmandade da Santa Casa da Misericordia de Santos

🇧🇷

Santos, Sao Paulo, Brazil

Nepean Hospital

🇦🇺

Kingswood, New South Wales, Australia

University Clinical Centre of the Republic of Srpska

🇧🇦

Banja Luka, Bosnia and Herzegovina

Options Health Research

🇺🇸

Tulsa, Oklahoma, United States

Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda

🇧🇷

Goiania, Goias, Brazil

San Antonio Gastroenterology

🇺🇸

San Antonio, Texas, United States

University Clinical Hospital Mostar

🇧🇦

Mostar, Bosnia and Herzegovina

UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

🇧🇷

Botucatu, Sao Paulo, Brazil

UMHAT "Sv. Ivan Rilski", EAD

🇧🇬

Sofia, Bulgaria

PerCuro Clinical Research Ltd.

🇨🇦

Victoria, British Columbia, Canada

"City Clinic UMHAC" EOOD

🇧🇬

Sofia, Bulgaria

Fourth MHAT - Sofia EAD

🇧🇬

Sofia, Bulgaria

Zeidler Ledcor Centre - University of Alberta

🇨🇦

Edmonton, Alberta, Canada

Regionshospitalet Silkeborg

🇩🇰

Silkeborg, Denmark

Medizinische Hochschule Hannover

🇩🇪

Hannover, Niedersachsen, Germany

CCBR - Czech Brno, s.r.o..

🇨🇿

Brno, Czechia

CCBR Czech Prague, s.r.o.

🇨🇿

Praha 3, Czechia

LHSC - Victoria Hospital

🇨🇦

London, Ontario, Canada

A-SHINE s.r.o.

🇨🇿

Plzen, Czechia

North Estonia Medical Centre Foundation

🇪🇪

Tallinn, Estonia

LHSC - University Hospital

🇨🇦

London, Ontario, Canada

Toronto Digestive Disease Associates, Inc.

🇨🇦

Vaughan, Ontario, Canada

Chaim Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi

🇮🇹

Bologna, Italy

Hepato-Gastroenterologie HK s.r.o.

🇨🇿

Hradec Kralove, Czechia

Policlinico Universitario Agostino Gemelli

🇮🇹

Roma, Italy

Axon Clinical s.r.o.

🇨🇿

Praha 5, Czechia

Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

🇭🇺

Szekesfehervar, Hungary

Krankenhaus Waldfriede e. V.

🇩🇪

Berlin, Germany

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

🇩🇪

Mainz, Rheinland Pfalz, Germany

Karolina Korhaz-Rendelointezet

🇭🇺

Mosonmagyarovar, Hungary

Tolna Megyei Balassa Janos Korhaz

🇭🇺

Szekszard, Hungary

Azienda Ospedaliera Ospedale Cannizzaro

🇮🇹

Catania, Italy

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

EUGASTRO GmbH

🇩🇪

Leipzig, Sachsen, Germany

Shaare Zedek Medical Center

🇮🇱

Jerusalem, Israel

Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco)

🇮🇹

Milano, Italy

Azienda Ospedaliera Vincenzo Cervello

🇮🇹

Palermo, Italy

DRK Kliniken Berlin Westend

🇩🇪

Berlin, Germany

Obudai Egeszsegugyi Centrum Kft.

🇭🇺

Budapest, Hungary

Pannonia Maganorvosi Centrum

🇭🇺

Budapest, Hungary

Azienda Ospedaliera San Camillo Forlanini

🇮🇹

Roma, Italy

I.R.C.C.S Policlinico San Donato

🇮🇹

San Donato Milanese (MI), Milano, Italy

Azienda Ospedaliera di Padova

🇮🇹

Padova, Italy

Hamamatsu South Hospital

🇯🇵

Hamamatsu-shi, Shizuoka-Ken, Japan

Ars-Medica S.C Rybak Maria, Rybak Zbigniew

🇵🇱

Wroclaw, Poland

JCHO Tokyo Yamate Medical Center

🇯🇵

Shinjuku-ku, Tokyo-To, Japan

Kyungpook National University Hospital

🇰🇷

Daegu, Korea, Republic of

Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

Vilnius University Hospital Santariskiu Clinic, Public Institution

🇱🇹

Vilnius, Lithuania

Kyung Hee University Hospital

🇰🇷

Seoul, Korea, Republic of

Morales Vargas Centro de Investigacion, S.C.

🇲🇽

Leon, Guanajuato, Mexico

Gabinet Endoskopii Przewodu Pokarmowego

🇵🇱

Krakow, Poland

SPZOZ Uniwersytecki Szpital Klin. nr 1 im.N.Barlickiego UM

🇵🇱

Lodz, Poland

Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

🇲🇽

Durango, Mexico

Sociedad de Metabolismo y Corazon S.C

🇲🇽

Veracruz, Mexico

Academisch Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Albert Schweitzer Ziekenhuis, Dordwijk

🇳🇱

Dordrecht, Netherlands

Erasmus Medisch Centrum

🇳🇱

Rotterdam, Netherlands

NZOZ Vitamed

🇵🇱

Bydgoszcz, Poland

Centralny Szpital Kliniczny MSW w Warszawie

🇵🇱

Warszawa, Poland

Twoja Przychodnia-Szczecinskie Centrum Medyczne

🇵🇱

Szczecin, Poland

Centrum Onkologii-Instytut im. M. Sklodowskiej Curie

🇵🇱

Warszawa, Poland

FSBSI "Scientific and Research Institute of Physiology and Basic Medicine"

🇷🇺

Novosibirsk, Russian Federation

Kazan State Medical University

🇷🇺

Kazan, Russian Federation

Institutul Clinic Fundeni

🇷🇴

Bucuresti, Romania

S.C Centrul de Gastroenterologie Dr. Goldis S.R.L

🇷🇴

Timisoara, Romania

SBEI of HPE "Omsk SMA" SBEI HPE "Omsk State Medical University" of the MoH of the RF

🇷🇺

Omsk, Russian Federation

Clinical Center of Vojvodina

🇷🇸

Novi Sad, Serbia

Military Medical Academy

🇷🇸

Belgrade, Serbia

Clinical Center Bezanijska kosa

🇷🇸

Belgrade, Serbia

Clinical Center Kragujevac

🇷🇸

Kragujevac, Serbia

Dr CCM Ziady Practice

🇿🇦

Pretoria, Gauteng, South Africa

Dr JP Wright Practice

🇿🇦

Cape Town, Western Cape, South Africa

Ankara University Medical Faculty

🇹🇷

Ankara, Turkey

Karolinska Universitetssjukhuset - Solna

🇸🇪

Stockholm, Sweden

Haydarpasa Numune Training and Research Hospital

🇹🇷

Istanbul, Turkey

Marmara University Pendik Research and Training Hospital

🇹🇷

Istanbul, Turkey

Kocaeli Derince Training and Research Hospital

🇹🇷

Kocaeli, Turkey

CI of Kyiv RC Kyiv Regional Clinical Hospital

🇺🇦

Kyiv, Ukraine

MI of Healthcare Kyiv RCH P.L. Shupyk NMA of PGE

🇺🇦

Kyiv, Ukraine

Mersin University Medical Faculty

🇹🇷

Mersin, Turkey

Kyiv CCH #12 Dept of Therapy O.O.Bogomolets NMU

🇺🇦

Kyiv, Ukraine

Whipps Cross University Hospital

🇬🇧

London, Greater London, United Kingdom

University Hospital Coventry

🇬🇧

Coventry, West Midlands, United Kingdom

CI City Hospital #1

🇺🇦

Zaporizhzhia, Ukraine

Private Small Enterprise Medical Center Pulse

🇺🇦

Vinnytsia, Ukraine

Yeungnam University Hospital

🇰🇷

Daegu, Korea, Republic of

Severance Hospital, Yonsei University

🇰🇷

Seoul, Korea, Republic of

Cotton-O'Neil Clinical Research Center, Digestive Health

🇺🇸

Topeka, Kansas, United States

Hospital of Lithuanian University of Health Sciences Kaunas Clinics

🇱🇹

Kaunas, Lithuania

L & L Research Choices, Inc.

🇺🇸

Miami, Florida, United States

Atlanta Gastroenterology Associates

🇺🇸

Atlanta, Georgia, United States

Mayo Clinic - Rochester

🇺🇸

Rochester, Minnesota, United States

University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Concord Repatriation General Hospital

🇦🇺

Concord, New South Wales, Australia

Ballarat Base Hospital

🇦🇺

Ballarat, Victoria, Australia

The Alfred Hospital

🇦🇺

Melbourne, Victoria, Australia

HUCFF-UFRJ - Hospital Universitario Clementino Fraga Filho - Universidade Federal do Rio de Janeiro

🇧🇷

Rio de Janeiro, Rio Do Janeiro, Brazil

Faculdade de Medicina do ABC

🇧🇷

Santo Andre, Sao Paulo, Brazil

MHAT "Hadzhi Dimitar", OOD

🇧🇬

Sliven, Bulgaria

Odense Universitetshospital

🇩🇰

Odense C, Denmark

Soroka University Medical Center

🇮🇱

Beer Sheva, Israel

Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak

🇭🇺

Budapest, Hungary

A.O.U. Policlinico di Modena

🇮🇹

Modena, Italy

Saga University Hospital

🇯🇵

Saga-shi, Saga-Ken, Japan

Toho University Sakura Medical Center

🇯🇵

Sakura-shi, Chiba-Ken, Japan

Fukuoka University Chikushi Hospital

🇯🇵

Chikushino-shi, Fukuoka-Ken, Japan

Iwate Medical University Hospital

🇯🇵

Morioka-shi, Iwate-Ken, Japan

Kitasato University Kitasato Institute Hospital

🇯🇵

Minato-ku, Tokyo-To, Japan

Wakayama Medical University Hospital

🇯🇵

Wakayama-shi, Wakayama-Ken, Japan

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Centrum Zdrowia MDM

🇵🇱

Warszawa, Poland

TSBIH "Territorial Clinical Hospital"

🇷🇺

Krasnoyarsk, Russian Federation

GASTROMED Sp. z o.o.

🇵🇱

Lublin, Poland

LLC "RIAT SPb"

🇷🇺

Saint-Petersburg, Russian Federation

CI Odesa Regional Clinical Hospital

🇺🇦

Odesa, Ukraine

Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU

🇺🇦

Lviv, Ukraine

St George's Hospital

🇬🇧

London, Greater London, United Kingdom

Royal Devon and Exeter Hospital (Wonford)

🇬🇧

Exeter, Devon, United Kingdom

Atlanta Gastroenterology Specialists, PC

🇺🇸

Suwanee, Georgia, United States

Tennyson Centre Day Hospital

🇦🇺

Bedford Park, South Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath